BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 10746412)

  • 41. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular study on the distinct isoforms of PML-RAR alpha fusion gene transcripts in acute promyelocytic leukemia].
    Geng JP
    Zhonghua Yi Xue Za Zhi; 1993 Apr; 73(4):197-200, 252. PubMed ID: 8395310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy.
    Nemet D; Grahovac B; Labar B; Mrsić M; Radman I; Bogdanić V; Hitrec V; Zaher D; Aurer I; Sertić D
    Haematologica; 1995; 80(3):238-40. PubMed ID: 7672716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytogenetic, fluorescent in situ hybridization & reverse transcriptase-polymerase chain reaction analysis in acute promyelocytic leukaemia patients.
    Shivakumar S; Poonkhuzhali B; Gunasekaran S; Srivastava A; Chandy M
    Indian J Med Res; 2002 Feb; 115():59-67. PubMed ID: 12138666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of PML-RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH.
    Han JY; Kim KE; Kim KH; Park JI; Kim JS
    Leuk Res; 2007 Feb; 31(2):239-43. PubMed ID: 16797070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA).
    Wang ZY; Chen Z; Huang W; Li XS; Lu JX; Huang LA; Zhang FQ; Gu LJ; Ouyang RR; Chen SJ
    Blood Cells; 1993; 19(3):633-41; discussion 642-7. PubMed ID: 8018944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute promyelocytic leukemia: from clinic to molecular biology.
    Chen SJ; Wang ZY; Chen Z
    Stem Cells; 1995 Jan; 13(1):22-31. PubMed ID: 7719245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimal residual disease in acute promyelocytic leukemia.
    Weil SC
    Clin Lab Med; 2000 Mar; 20(1):105-17, ix. PubMed ID: 10702899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Pérez-Romano B; Ruiz-Argüelles A; Ramírez-Cisneros FJ; López-Martínez B; López-Tapia JD; Rivadeneyra-Espinoza L
    Rev Invest Clin; 2000; 52(2):118-24. PubMed ID: 10846434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation.
    Takatsuki H; Umemura T; Sadamura S; Yamashita S; Goto T; Abe Y; Yufu Y; Inaba S; Nishimura J; Nawata H
    Leukemia; 1995 May; 9(5):889-92. PubMed ID: 7539517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia.
    Koller E; Karlic H; Krieger O; Mistrik M; Michlmayr G; Gadner H; Lutz D; Heinz R; Pittermann E
    Ann Hematol; 1995 Feb; 70(2):75-8. PubMed ID: 7880927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Proposals for the objective indices for evaluating the differentiation of leukemic cells by all-trans retinoic acid in the patients with acute promyelocytic leukemia].
    Nakajima H; Kizaki M; Takayama N; Kawai Y; Watanabe K; Okamoto S; Ikeda Y
    Rinsho Ketsueki; 1996 Mar; 37(3):208-13. PubMed ID: 8727344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells.
    Nason-Burchenal K; Takle G; Pace U; Flynn S; Allopenna J; Martin P; George ST; Goldberg AR; Dmitrovsky E
    Oncogene; 1998 Oct; 17(14):1759-68. PubMed ID: 9778041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of minimal residual disease in a patient with acute promyelocytic leukemia by RT-PCR: necessity of chemotherapy following ATRA therapy.
    Sun T; Takatsuki H; Yamashita S; Yufu Y; Umemura T; Nishimura J; Nawata H
    Fukuoka Igaku Zasshi; 1994 Feb; 85(2):52-6. PubMed ID: 8144129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
    Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
    Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cytogenetic and molecular genetic studies on a variant of t(15;17), ins(17;15)(q21;q14q22), in an acute promyelocytic leukemia patient].
    Chen SN; Xue YQ; Wu YF; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Feb; 21(1):77-9. PubMed ID: 14767917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy.
    Degos L
    Int J Cell Cloning; 1992 Mar; 10(2):63-9. PubMed ID: 1312109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.